Premium
Iron‐ovotransferrin preparation does not interfere with ciprofloxacin absorption
Author(s) -
Pazzucconi Franco,
Barbi Silvia,
Baldassarre Damiano,
Colombo Nicola,
Dorigotti Fabio,
Sirtori Cesare R.
Publication year - 1996
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/s0009-9236(96)90110-1
Subject(s) - ovotransferrin , chemistry , cmax , bioavailability , transferrin , absorption (acoustics) , pharmacokinetics , pefloxacin , pharmacology , ciprofloxacin , biochemistry , antibiotics , medicine , physics , acoustics , ofloxacin
Iron supplements can interfere with the bioavailability of a number of drugs, including thyroxine, tetracycline derivatives, penicillamine, methyldopa, levodopa, carbidopa, ciprofloxacin, and the newer fluoroquinolones. A new iron formulation was tested in which iron ions are bound to ovotransferrin, a protein that shares more than an 80% similarity with the sequence of human transferrin and apparently is less likely than the commonly used iron salts to reduce drug absorption. Ciprofloxacin was taken as a model drug, of wide use and restricted range of therapeutic levels, and its absorption was evaluated after the administration of the iron‐ovotransferrin complex versus an iron‐gluconate formulation in healthy volunteers. At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (C max ; 1.0 ± 0.2 versus 2.4 ± 0.3 μg/ml; p < 0.01) and of the area under the serum concentration‐time curve from time 0 to infinity [AUC(0‐∞); 10.1 ± 1.1 versus 18.3 ± 1.0 mg · L −1 · hr; p < 0.01], the iron‐ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC(0‐∞) (17.3 ± 1.0 versus 18.3 ± 1.0 mg · L −1 · hr; difference not significant) and a nonsignificant decrease in the C max (2.2 ± 0.3 versus 2.4 ± 0.3 μg/ml; difference not significant). Iron was also well absorbed from the formulation in the presence of a fatty meal. The very common drug interactions with oral iron preparations can be effectively prevented by the use of the iron‐ovotransferrin complex interacting to a minimal extent with a sensitive drug with a reduced margin of efficacy, such as ciprofloxacin. Clinical Pharmacology & Therapeutics (1996) 59 , 418–422; doi: